
The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
Pharmaceutical science & technology news.
about 23 years ago
In the Spotlight September 2003about 23 years ago
Counterfeiting, Compliance, and Controlsabout 23 years ago
September 2003about 23 years ago
Disposable Filtration Lightens Cleaning and Validation Loadabout 23 years ago
CROs Hoping for Research Burst in Second Half of 2003





